前蛋白转化酶枯草溶菌素9抑制剂降低血清LDL-C的作用机制及临床疗效

基础医学与临床 ›› 2018, Vol. 38 ›› Issue (9): 1342-1347.

前蛋白转化酶枯草溶菌素9抑制剂降低血清LDL-C的作用机制及临床疗效

刘宁¹,旦菊花¹,李秋霞²,唐文如¹

1. 昆明理工大学医学院
2. 云南省大理州人民医院

收稿日期:2017-11-27 修回日期:2018-03-26 出版日期:2018-09-05 发布日期:2018-09-10
通讯作者: 唐文如 E-mail:twr@sina.com
基金资助:
省级基础研究

Mechanism and clinical effect of proprotein convertase subtilisin/kexin type 9 inhibitors to reduce serum LDL-C

Received:2017-11-27 Revised:2018-03-26 Online:2018-09-05 Published:2018-09-10
Supported by:
Provincial basic research

摘要/Abstract

摘要： 低密度脂蛋白胆固醇（LDL-C）水平与心血管疾病紧密相关。他汀类药物作为降脂首选药，临床结果表明部分患者不能耐受最大剂量他汀或者用药后不能达到正常LDL-C水平。前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂可显著降低血清LDL-C水平，且耐受性和安全性较好。目前PCSK9抑制剂在国外已经用于临床。

关键词: 关键词：低密度脂蛋白胆固醇, 人类枯草溶菌素转化酶9, 人类枯草溶菌素转化酶9抑制剂, 低密度脂蛋白受体

Abstract: Low density lipoprotein cholesterol (LDL-C) has been demonstrated to be closely involved with Atherosclerotic cardiovascular disease (ASCVD). Clinical guidelines indicate that Statins serve as the first choice to lower LDL-C, there remains some patients can not be tolerable to statins, or even large doses of statins fail to achieve the optimal level of LDL-C. PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors can significantly reduce serum LDL-C level with good tolerance and safety. Recently, PCSK9 inhibitors have been approved to be used clinically by FDA.

Key words: Key words：LDL-C, PCSK9, PCSK9 inhibitor, LDLR

中图分类号:

CN 11-2652/R

刘宁旦菊花李秋霞唐文如. 前蛋白转化酶枯草溶菌素9抑制剂降低血清LDL-C的作用机制及临床疗效[J]. 基础医学与临床, 2018, 38(9): 1342-1347.